Clinical Trials Directory

Trials / Conditions / Prostatic Neoplasm

Prostatic Neoplasm

73 registered clinical trials studyying Prostatic Neoplasm8 currently recruiting.

StatusTrialSponsorPhase
RecruitingInvestigation of Impact of AI on Prostate Cancer Workflow
NCT07084779
Case Comprehensive Cancer CenterN/A
RecruitingPSMA PET Combined With MRI for the Detection of PCa
NCT07052214
Telix Pharmaceuticals (Innovations) Pty LimitedPhase 3
Active Not RecruitingTowards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
NCT05968144
University of Maryland, BaltimorePhase 1 / Phase 2
Active Not RecruitingA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive C
NCT05849298
Novartis PharmaceuticalsPhase 2
RecruitingUsing Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progr
NCT06292897
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
RecruitingDETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/
NCT05786716
Cancer Research UKPhase 2 / Phase 3
RecruitingClinical, Genetic and Environmental Determinants of Prostate Cancer Progression.
NCT06046131
Centre Hospitalier Universitaire de la GuadeloupeN/A
UnknownEarly Salvage Stereotactic Radiotherapy for Biochemical Failure After RP
NCT05667636
Regina Elena Cancer InstitutePhase 2
UnknownA Study on Drug-drug Interactions in Patients Treated With Anticancer Agents for a Prostate Cancer in Real Lif
NCT05612841
Centre Hospitalier Universitaire de Besancon
RecruitingImpact of Augmented Reality During Robot-assisted Radical Prostatectomy
NCT06059859
European Institute of OncologyN/A
CompletedEBRT + Lu-PSMA for N1M0 Prostate Cancer
NCT05162573
The Netherlands Cancer InstitutePhase 1
Unknown68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical
NCT04831307
British Columbia Cancer AgencyN/A
CompletedUrinary and Prostate Microbiotes and Prostate Cancer
NCT03947515
Centre Hospitalier Universitaire de NiceN/A
Active Not Recruiting[68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer
NCT04484701
British Columbia Cancer Agency
UnknownSLPI for Prostate Cancer
NCT04854343
University of Florence
TerminatedTrial of NanoPac Focal Therapy for Prostate Cancer
NCT04221828
NanOlogy, LLCPhase 2
CompletedAssessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
NCT03935282
Wake Forest University Health SciencesN/A
UnknownEvaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk
NCT04462926
Azienda Ospedaliero-Universitaria di ModenaN/A
CompletedThe Effects of Method of Anaesthesia on the Safety and Effectiveness of Radical Retropubic Prostatectomy
NCT05566405
Sismanoglio General HospitalN/A
TerminatedDetermination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy
NCT04234399
University of Vermont
CompletedEMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression
NCT04266431
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsN/A
RecruitingProstate Cancer Genetic Risk Evaluation and Screening Study
NCT05129605
Massachusetts General Hospital
TerminatedOrganoids From Metastases of Prostate Cancer
NCT03952793
Centre Antoine LacassagneN/A
CompletedMSG Use With 18F-DCFPyL PET/CT Imaging
NCT03693742
British Columbia Cancer AgencyN/A
CompletedSurvey on Lifestyle, Perceived Barriers and Development of Change in Patients With Prostate Cancer
NCT03982095
Azienda USL Reggio Emilia - IRCCS
UnknownHDR Brachytherapy Plus Stereotactic Ablative Prostate Radiotherapy for Patients With Intermediate and High-ris
NCT04523896
David BüchserPhase 2
CompletedI-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
NCT03939689
Progenics Pharmaceuticals, Inc.Phase 2
UnknownThe Immunodynamic Effect of Radiotherapy in Prostate Cancer Patients.
NCT04774133
Regina Elena Cancer InstituteN/A
CompletedDosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit
NCT03183544
Cliniques universitaires Saint-Luc- Université Catholique de LouvainPhase 1
CompletedRestore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors
NCT03343093
University of MinnesotaN/A
CompletedProstate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
NCT03253744
National Cancer Institute (NCI)Phase 1
Terminated177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
NCT03490838
Advanced Accelerator ApplicationsPhase 1
CompletedComparison of Multi-parametric and Bi-parametric Magnetic Resonance Imaging in Men With Suspicion of Prostate
NCT03693703
Fondazione del Piemonte per l'OncologiaN/A
CompletedEvaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients
NCT03361969
Pantarhei Oncology B.V.Phase 2
Completed68Ga PSMA in Preprostatectomy Patients
NCT03388346
Michael Graham PhD, MDPhase 2 / Phase 3
Completed68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
NCT03389451
Michael Graham PhD, MDPhase 2 / Phase 3
TerminatedMeasurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biop
NCT03242265
ATGen Canada IncN/A
CompletedProstatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer
NCT03104907
Rigshospitalet, DenmarkN/A
UnknownAn Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previous
NCT03061643
Samsung Medical CenterPhase 2
CompletedDetection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study
NCT02967458
Thomas Jefferson UniversityPhase 2
CompletedImpact of Exercise on Prognostic Biomarkers Related to Prostate Cancer
NCT03397030
The University of Texas Health Science Center at San AntonioN/A
CompletedUrology of Virginia Case Series
NCT03035487
Exact ImagingN/A
CompletedPositive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiv
NCT02977143
Seoul National University HospitalN/A
RecruitingObservation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castrati
NCT06236789
Yonsei University
CompletedThe Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep
NCT02966535
Seoul National University HospitalN/A
CompletedTreatment Patterns in Metastatic Prostate Cancer
NCT02729103
Bayer
CompletedOpen Anterograde Radical Prostatectomy Compared to Open Retrograde Technique
NCT02687308
Rio de Janeiro State UniversityN/A
CompletedDoes Bloody Urine Predict Urethrovesical Anastomosis Leakage After Radical Prostatectomy
NCT02526589
Tampere University Hospital
CompletedActive Surveillance or Radical Treatment for Newly Diagnosed Patients With a Localized, Low Risk, Prostate Can
NCT03348722
Rete Oncologica Piemonte, Valle d'Aosta
TerminatedCarboplatin in Castration-resistant Prostate Cancer
NCT02311764
Aurelius OmlinPhase 2
CompletedTrimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies
NCT02971995
Lille Catholic UniversityN/A
CompletedDetection Rate of Prostate Cancer in Men Undergoing MRI
NCT04398173
Fondazione del Piemonte per l'Oncologia
TerminatedPrevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Thera
NCT01996696
AHS Cancer Control AlbertaPhase 2
CompletedSequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
NCT01431391
DendreonPhase 2
CompletedIMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
NCT01314118
Janssen Biotech, Inc.Phase 2
SuspendedA Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate C
NCT01337518
Enzon Pharmaceuticals, Inc.Phase 1
CompletedStereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
NCT01540994
Sharp HealthCareN/A
CompletedSteps for PRosTAte Cancer Health and Survival (SPaRTACuS): Pilot Study of a Walking Intervention to Improve He
NCT01696539
Örebro University, SwedenN/A
CompletedStudy of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer
NCT00956228
Mayo ClinicPhase 1 / Phase 2
CompletedEfficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer
NCT00751790
Debiopharm International SAPhase 3
CompletedExercise for Physical Health in Men With Prostate Cancer
NCT00660686
OHSU Knight Cancer InstituteN/A
CompletedStudy Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
NCT00666926
Verastem, Inc.Phase 1
CompletedPd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
NCT00247312
Schiffler Cancer CenterPhase 3
CompletedHigh Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implant
NCT00126854
AHS Cancer Control AlbertaN/A
CompletedDietary Factors and Racial Disparities in Prostate Cancer Aggressiveness
NCT03289130
University of South Carolina
CompletedStudy to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the
NCT01081873
Abbott
CompletedCT/MRI Co-registration Prostate Cancer
NCT00252460
University Health Network, Toronto
CompletedEvaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
NCT00174863
SanofiPhase 2
CompletedGlivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
NCT01316458
Novartis PharmaceuticalsPhase 2
CompletedPreop Conformal Radiotherapy - Prostate
NCT00252447
University Health Network, TorontoPhase 1 / Phase 2
CompletedA Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
NCT00001446
National Cancer Institute (NCI)Phase 2
CompletedA Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
NCT00001444
National Cancer Institute (NCI)Phase 1
CompletedA Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
NCT00001266
National Cancer Institute (NCI)Phase 2